Japan med reform bill passes Lower House

28 May 2006

Japan's medical reform bill, consisting of revisions to the Health Insurance Law and the Medical Service Law and mainly aimed at capping the growth of medical costs, has passed the House of Representatives. The bill will now be sent to the House of Councilors to be approved during the current Diet (parliament) session.

The bill calls for increases of the co-payment for people aged 70 or older with over a certain amount of annual income from 20% to 30%, starting in October this year, and the co-payment for those aged 70-74, with a defined annual income from 10% to 20%, commencing in the fiscal year 2008.

In addition, the bill will introduce a new health insurance program independently for those aged 75 or older, and 65-74 in the fiscal year 2008. The bill also allows the expansion of "mixed-medical treatment" (health insurance-covered and non-covered medical treatment to be conducted simultaneously).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight